Zhongjie Qiao1, Dan Wang, Junghyun Hahn, Junkui Ai, Zhou Wang. 1. Department of Urology, The 3rd Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang, China; Department of Urology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: The tumor suppressor ELL associated factor 2 (EAF2/U19) has been reported to induce apoptosis of LNCaP cells and suppress AT6.1 xenograft prostate tumor growth. EAF2/U19 expression level is down-regulated in advanced human prostate cancer. EAF2/U19 is also a putative transcription factor with a transactivation domain and capability of sequence-specific DNA binding. Identification of binding partners and regulators of EAF2/U19 is essential to understand its function in regulating apoptosis/survival of prostate cancer cells. METHODS: Through a yeast two-hybrid screening system, we identified Pirin as a binding partner of EAF2. We further determined the interaction between epitope-tagged EAF2/U19 and Pirin by co-immunoprecipitation in mammalian cells. The effect of Pirin on EAF2/U19 inhibition of LNCaP growth was assayed by colony formation. RESULTS: Pirin co-immunoprecipitated with EAF2/U19 and the overexpressed Pirin decreased the expression level of EAF2/U19 protein in prostate cancer cell lines LNCaP and PC3. Furthermore, overexpression of EAF2/U19 suppressed LNCaP colony formation, and co-expression of Pirin significantly blocked the growth inhibition induced by EAF2/U19 overexpression. CONCLUSION: Pirin is a newly identified binding partner of EAF2/U19 capable of down-regulating EAF2/U19 protein and alleviating its inhibition of prostate cancer cell survival/proliferation. Pirin may play an important role involved in EAF2/U19 function as an androgen-responsive gene and tumor repressor.
BACKGROUND: The tumor suppressor ELL associated factor 2 (EAF2/U19) has been reported to induce apoptosis of LNCaP cells and suppress AT6.1 xenograft prostate tumor growth. EAF2/U19expression level is down-regulated in advanced humanprostate cancer. EAF2/U19 is also a putative transcription factor with a transactivation domain and capability of sequence-specific DNA binding. Identification of binding partners and regulators of EAF2/U19 is essential to understand its function in regulating apoptosis/survival of prostate cancer cells. METHODS: Through a yeast two-hybrid screening system, we identified Pirin as a binding partner of EAF2. We further determined the interaction between epitope-tagged EAF2/U19 and Pirin by co-immunoprecipitation in mammalian cells. The effect of Pirin on EAF2/U19 inhibition of LNCaP growth was assayed by colony formation. RESULTS:Pirin co-immunoprecipitated with EAF2/U19 and the overexpressed Pirin decreased the expression level of EAF2/U19 protein in prostate cancer cell lines LNCaP and PC3. Furthermore, overexpression of EAF2/U19 suppressed LNCaP colony formation, and co-expression of Pirin significantly blocked the growth inhibition induced by EAF2/U19 overexpression. CONCLUSION:Pirin is a newly identified binding partner of EAF2/U19 capable of down-regulating EAF2/U19 protein and alleviating its inhibition of prostate cancer cell survival/proliferation. Pirin may play an important role involved in EAF2/U19 function as an androgen-responsive gene and tumor repressor.
Authors: R Dechend; F Hirano; K Lehmann; V Heissmeyer; S Ansieau; F G Wulczyn; C Scheidereit; A Leutz Journal: Oncogene Date: 1999-06-03 Impact factor: 9.867
Authors: W Xiao; Q Zhang; G Habermacher; X Yang; A-Y Zhang; X Cai; J Hahn; J Liu; M Pins; L Doglio; R Dhir; J Gingrich; Z Wang Journal: Oncogene Date: 2007-09-17 Impact factor: 9.867
Authors: Christine Jungk; Andreas Mock; Janina Exner; Christoph Geisenberger; Rolf Warta; David Capper; Amir Abdollahi; Sara Friauf; Bernd Lahrmann; Niels Grabe; Philipp Beckhove; Andreas von Deimling; Andreas Unterberg; Christel Herold-Mende Journal: BMC Med Date: 2016-10-26 Impact factor: 8.775
Authors: Matthew D Cheeseman; Nicola E A Chessum; Carl S Rye; A Elisa Pasqua; Michael J Tucker; Birgit Wilding; Lindsay E Evans; Susan Lepri; Meirion Richards; Swee Y Sharp; Salyha Ali; Martin Rowlands; Lisa O'Fee; Asadh Miah; Angela Hayes; Alan T Henley; Marissa Powers; Robert Te Poele; Emmanuel De Billy; Loredana Pellegrino; Florence Raynaud; Rosemary Burke; Rob L M van Montfort; Suzanne A Eccles; Paul Workman; Keith Jones Journal: J Med Chem Date: 2016-12-22 Impact factor: 7.446